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Background: Significance of Urocortin (Ucn or UcnI), Ucn2, Ucn3 and their receptors, Corticotropin Releasing
Factor Receptor 1 and 2 (CRFR1 and CRFR2), and the binding protein, Corticotropin-Releasing Hormone-Binding
Protein (CRHBP) in oncology is growing rapidly. The objective of our study was to assess the expression of the
CRHBP mRNA and protein in renal cancer.
Methods: Tumoral tissues of 78 patients with clear cell renal cell cancer and their corresponding normal tissues
were analyzed using quantitative mRNA expression analysis for detection of mRNA expression level. Protein
expression and tissue localization of CRHBP protein in renal specimens was evaluated using western blotting,
immunohistochemistry and double immunofluorescence, respectively.
Results: We found an approx. 33 fold decrease of average CRHBP mRNA level in tumoral tissues compared to
paired normal tissues (p<0.001). Diminished CRHBP mRNA expression was positively correlated with advanced,
metastasized and higher stage of disease (p<0.001, p=0.026, p=0.028 respectively). CRHBP protein was detected
in glomeruli and proximal tubules of normal kidney while none or weak immunopositivity was found in cc-RCC
(p<0.001).
Conclusions: The expression analysis of CRHBP shows that cc-RCC is characterized by a significant loss of CRHBP
mRNA expression that furthermore is associated with a more aggressive state of tumors. Depletion of CRHBP
proteins also indicate that the protein as part of the UCN system may be involved in renal carcinogenesis.Background
The Corticotropin releasing factor (CRF) system in
human includes all naturally occurring CRF peptide
analogues namely Urocortin (Ucn) and Urocortin 3
(Ucn3), known as CRF counterparts in the periphery,
the CRF receptors 1 and 2 (CRFR1 and CRFR2), and
finally Corticotropin-releasing hormone-binding protein
(CRHBP) [1-4]. The existence and translation of Urocortin
2 (Ucn2) in human is still unclear. It has been shown that
CRF analogues can inhibit tumor progression, can modu-
late proliferation and apoptosis, and can hinder angiogen-
esis by reduction of VEGF expression in vivo, through
activation of CRF receptors, especially CRFR2 in different* Correspondence: tezval.hossein@mh-hannover.de
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reproduction in any medium, provided the ortumor entities [5-8]. Expression and the pathophysiological
relevance of the CRF system has been reviewed for different
human cancers [9,10]. Recently, we reported the expression
of Ucn and CRFR2 in clear cell renal cell carcinoma
(cc-RCC) [11]. In our study, a nuclear migration of Ucn
and loss of expression of vascular CRFR2 in cc-RCC could
be demonstrated [11]. Expression of CRHBP on mRNA
level has been reported in human normal kidney [12] but
there is still no data available about the expression of
CRHBP in kidney cancer. Moreover, for other tumor en-
tities it has been pointed out that expression patterns of the
CRF system are related to grade and stage of tumors [10].
To assess a potential relevance of CRHBP expression
alterations for cc-RCC we first compared the mRNA
expression levels of CRHBP in cc-RCC fresh frozen
specimens and paired normal appearing tissue samples
using quantitative RT-PCR analysis. Moreover, relativetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical and histopathological data of patients
with renal cell cancer used for qPCR
Clinico-pathological parameters Number of patients %
Total 109 100







Partial nephrectomy 27 24.8
Radical nephrectomy 82 75.2
Histological subtypes
clear cell 78 71.6
papillary 22 20.2
chromophobe 2 1.8







Synchronous Lymph nodes metastasis 11 10.1
Synchronous distant metastasis 23 21.1
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association with clinicopathological parameters of cc-
RCC patients. Presence and localization of CRHBP
protein expression in normal and malignant kidney tis-




The present study included sample cohorts both of fresh
frozen and paraffin embedded tissues. Fresh frozen sam-
ples of tumors and a subset of corresponding tumor free
tissues were obtained from 109 patients subjected to
kidney surgery between 2001 and 2005 in the Eberhard
Karls University Tuebingen. Tissue preparation, storage,
pathological evaluation, tumor stage assessment ac-
cording to the UICC 2002, nuclear grading, and data
management have been previously described [13]. The
ethical committee of the institution (the Eberhard
Karls University Tuebingen) approved the study and
informed consent of patients was obtained. The study
was carried out in compliance with the Helsinki
Declaration. For mRNA expression analysis we selected
fresh frozen specimens of 78 tumors with the histo-
logical subtype of cc-RCC and available paired normal
appearing tissue samples. Organ-confined RCC was
defined as pT≤2 and N0/M0 and advanced as pT ≥ 3
and/or N+/M+. Clinical and histopathological data of
this group are summarized in Table 1.
Paraffine embedded tissue samples of tumor, invasion
front and adjacent histopathologically normal tissues
were obtained from an independent group of patients,
subjected to nephrectomy and arranged as tissue
microarrays as described before [13,14]. Clinical and
histopathological data of the subset of 33 patients with
cc-RCC considered for immunhistochemical (n=16 pa-
tients) or immunofluorescence (n=17 patients) analysis
of paraffin embedded tissue microarray specimens are
shown in Table 2.
Nucleic acid extraction and quantitative real time PCR
RNA extraction from the fresh frozen tissue group
and cDNA synthesis were performed as described
before [15]. Briefly, quantitative real time RT-PCR
analyses were performed in duplicate with an ABI 7900
Fast Sequence Detection System using TaqMan gene
expressionn assays and universal PCR master mix
according to the manufacturer's specifications (life
technologies) [15]. The TaqMan assays used were
CRHBP (Assay ID: Hs00181810_m1), GUSB (Assay ID:
Hs00939627_m1), RPL13A (Assay ID: Hs03043885_g1)
and HPRT1 (Assay ID: Hs99999909_m1). The human
GUSB, RPL13A and HPRT1 transcripts served as en-
dogenous controls. Additional no-template, no reversetranscription and blank controls were included in each
run.
Relative quantities of transcripts were calculated using
the SDS 2.3 Manager, data assist v2.0 Software and the
delta-delta Ct method [16,17]. The reference Ct values
both for CRHBP and the endogenous controls were cal-
culated from the whole tissue sample group and applied
as a surrogate biological control for computation of rela-
tive quantities.
Western blot analysis
Western blotting was performed according to standard
protocols. Briefly, blots were incubated with primary
goat antihuman antibody for CRHBP (1:1000 dilutions,
AF2796, R&D systems GmbH, Wiesbaden-Nordenstadt,
Germany) and biotinylated horse anti-goat IgG Antibody
Table 2 Clinical and histopathological data of paraffine
embedded tissue samples of renal cell cancer cases
Variable All patients1 IHC-TMA1 IF-TMA1
n (%) n (%) n (%)
Total 33 (100) 16 (48) 17 (52)
Gender Female 13 (39) 7 (43) 6 (35)
Male 20 (61) 9 (57) 11 (65)
Age (mean) 59.03 61.7 56
pT stage T1 0 (0) 0 (0) 0 (0)
T2 16 (48) 7 (43) 9 (53)
T3 15 (45) 9 (57) 6 (35)
T4 2 (6) 0 (0) 2 (12)
Lymph node N0 12 (36) 4 (25) 8 (47)
N1 3 (9) 3 (18) 0 (0)
Nx 18 (55) 9 (56) 9 (53)
Metastasis M0 23 (69) 11 (69) 12 (70)
M1 8 (24) 4 (25) 4 (24)
Mx 2 (7) 1 (6) 1 (6)
Tumor grade G1 4 (12) 4 (25) 0 (0)
G2 25 (76) 10 (62) 15 (88)
G3 3 (9) 1 (6) 2 (12)
G4 0 (0) 0 (0) 0 (0)
Unknown 1 (3) 1 (6) 0 (0)
1subgroup with clear cell histology; IHC, immunohistochemical analysis;
IF, immunofluorescence analysis; TMA, tissue microarray analysis.
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GmbH, Lörrach, Germany). For detection of the
loading control we used mouse monoclonal anti beta
Tubulin (1:1000 dilution, DSHB, Iowa, US) as primary
and peroxidase labeled antimouse antibody as second-
ary antibody (1:10000 dilution, NIF 825, Amersham,
GeHealthcare, Freiburg, Germany). Antibody-protein
complexes were visualized using a super west dura kit
(Thermo scientific, 34076) and Amersham Hyperfilm
(Ge Healthcare) following scanning of the film.
Immunohistochemical and immunofluorescence analyses
Immunohistochemical (IH) and immunofluorescence
(IF) analyses of tissue microarrays were carried out as
described before [11,13,18]. For IF analysis, anti-human
CRHBP, a goat polyclonal antibody (1:100 dilutions,
AF2796, R&D systems GmbH, Wiesbaden-Nordenstadt,
Germany) and secondary antibody as described above
for western blotting was applied. Rabbit anti-human
MUC-1 polyclonal antibody (1:100 dilutions, ab15481,
abcam, Cambridge, UK) and rabbit polyclonal anti-
human nephrin (1:100 dilutions, ab58968, abcam,
Cambridge, UK) were used for double IF staining for
specific detection of distal tubuli (Muc-1) and glomeruli
(Nephrin) [19,20]. As secondary antibody we usedbiotinylated anti mouse-anti rabbit (1:200 dilutions,
Vector, BA 1400, enzo life sciences GmbH, Lörrach,
Germany). The paraffin embedded tissue sections were
demasked and stained following Avidin/Biotin blocking
(Vector Laboratories, Burlingame, CA) by the use of
ABC and tyramide based ATTO-488 and ATTO-655
fluorescent dyes as specified before [11,18]. A negative
control was included using omitting the primary
antibody.
Statistical analysis
For comparison of kidney tumor tissues and paired
tumor adjacent normal tissue samples the paired t-test
was applied for evaluation of relative mRNA quantita-
tion results while the NcNemar Chi - square test
was used for nonparametric pairwise comparison of im-
munostaining results. For the immunohistochemically
stained tissue microarray only signals in normal tubular
epithelial or tumor cells were considered. Tissue samples
from the immunofluorescence stained tissue microarray
were evaluated for the overall intensity of CRHBP re-
lated fluorescence detected within the field of view inde-
pendent from morphological informations of DAPI
staining of nuclei. Univariate logistic regression models
were carried out for independent group comparisons of
measured mRNA levels as described before [15]. Means
and standard deviations (sd) per group, odds ratios
(OR), corresponding 95% confidence intervals (CI) and
two-sided p-values are presented. P ≤ 0.05 was consid-
ered to be statistically significant.
Results
Analysis of mRNA expression of CRHBP in normal kidney
and kidney cancer
Using 5´ exonuclease fluorogenic real-time PCR assays
(qPCR) for quantitative expression analysis of CRHBP
mRNA levels, we found in pairwise comparisons in most
of cases a loss of expression in tumor tissues as indi-
cated by the negative differences of sorted pairwise rela-
tive expressions in tumor and normal tissue (Figure 1A).
Group comparison of tumors (clear cell carcinoma
subtype (n=78)) and paired normal tissue samples
showed a mean relative expression of 0.0091 and 0.334
respectively (Figure 1B) corresponding to a 33 fold
reduction for the mean relative mRNA levels of CRHPB
in tumor tissues. Statistical analysis using the paired
t-test confirmed that means of both groups are different
(p <0.001).
Analysis of CRHBP protein expression and tissue
localization in kidney tissues
To characterize the specificity of the CRHBP antibody
we first carried out western blot analysis in test lysates




























































































































Figure 1 Relative CRHBP mRNA expression levels in renal tissues and comparison with clinicopathological parameters. A) Assorted
difference plot for illustration of relative mRNA expression level differences between tumour and paired adjacent normal tissue samples of cc-
RCCs. B) Groupwise bean plot comparison of relative CRHBP mRNA expression level in cc-RCC (TU) and normal kidney (aNT)shows approx. 33 fold
reduction in CRHBP mRNA level (p<0.001). C) CRHBP mRNA level comparison in M+ and M- in cc-RCC indicates a significant reduction of CRHBP
in metastasized state of the disease, p=0.026. D) CRHBP mRNA level comparison in advanced and localized disease demonstrates a higher
expression of CRHBP in localized cc-RCC, p<0.001. E) CRHBP mRNA level comparison in high (T3) and low stage (T1) tumors (cc-RCC) shows a
significant reduction of CRHBP in higher stages of disease, p=0.028.
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single band of expected molecular weight of 37 kD for
each of the normal tissues as exemplarily shown in
Figure 2A (lanes 1 and 3) for two tissue pairs thus
indicating the specificity of the antibody used. None of
the four tumors exhibited a detectable signal in the
range of the molecular weight of CRHBP (Figure 2A,
lanes 2 and 4).Next we used immunofluorescence analysis of a tissue
microarray representing 17 cc-RCC to characterize the dis-
tribution of immunopositivity of CRHBP in normal and
tumor tissues. Considering that a previous study detected
mRNA expression both in glomeruli and podocytes of nor-
mal tissues, we also exemplified costaining of CRHBP both
with the anti-nephrin antibody for detection of glomeruli









Figure 2 CRHBP protein expression and tissue localization in cc-RCC and normal kidney. A) Western blotting shows a tumor specific loss
of CRHBP protein in lane 2 and 4. Positive signals for CRHBP were observed in most of the normal specimens. Detection of β-Tubulin has been
used as an internal loading control. B) CRHBP immuno-signalling in proximal tubuli (green arrows), glomeruli (yellow arrows) and lack of
immunopositivity in distal tubules of normal kidney (red arrows). C) Immunopositivity for nephrin detected in glomeruli and proximal tubules in
normal kidney. D) Double immunofluorescence staining of nephrin (red) and CRHBP (green) demonstrating co-expression in glomeruli and
proximal tubules of normal renal tissues. E) Double immunofluorescence staining of CRHBP (green) and distal marker protein MUC-1 (red) in
normal kidney F) Invasion front tissue demonstrating reduction of CRHBP protein immunosignaling when normal (left side) and tumor tissue
areas (right side) are compared G) CRHBP immunofluorescence staining (green) with nuclear counterstaining using Dapi (blue) in tumor tissue
of cc-RCC.
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cc-RCC independent from the tissue microarray samples
[19]. As a result we found CRHBP immunopositivity in
glomeruli and podocytes, as well as intensive signals in
MUC1-1 negative tubular structures of normal appearing
tissues (Figure 2B-E). In contrast none or faint signals
were observed in tumor tissues (Figure 2G). To assign
immunopositivity to morphologically defined areas within
tissue samples we also used normal immunohistochemistry
for staining of another tissue microarray consisting of each
16 tumor, invasion front and paired normal samples fromcc-RCC. Tissue specimens showed high immunopositivity
located in tubules of normal tissue areas but low or lacking
positivity in the tumor areas as examplary demonstrated
for an invasion front sample in Figure 2F.
Comparison of immunopositivity in tumor and paired
normal tissues could be carried out in 15 out of 16 and
15 out of 17 cases analysed by immunohistochemistry or
immunofluorescence, respectively. The comparison re-
vealed that 15 out of 15 (100%, immunohistochemically
stained tissue microarray) and 13 out 15 (87%, immuno-
fluorescence analysis) tissue pairs with cc-RCC histology
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in normal tissues.
Two tissue pairs were either detected negative or showed
comparable immunofluorescence signals in tumor and nor-
mal tissues. Statistical comparison of differences demon-
strated a significant difference in immunopositivity between
tumor and paired normal tissues in both microarrays
(p<0.001, p<0.001, McNemar chi-square analysis). Consid-
ering that only one tumor tissue out of 28 was detected
to exhibit immunopositivity, analysis of further tissue
microarrays for detection of a possible association of tu-
moral immunopositivity with clinicopathological parame-
ters was not carried out.
Clinicopathological relevance of relative CRHBP mRNA
expression levels in cc-RCC
In contrast to the detection of CRHBP immunopositivity,
mRNA levels in tumor tissue could be differentiated. We
therefore statistically compared relative mRNA expression
levels with histology and clinicopathological parameters of
tumor patients (Figure 1). Our statistical evaluation of
CRHBP mRNA levels within the tumor group revealed that
reduced CRHBP levels are associated with advanced, me-
tastasized and higher stages of disease (p<0.001, p=0.026,
p=0.028 respectively, Figure 1C-E).
Discussion
Here we demonstrate that CRHBP expression is depleted
both on mRNA and most likely also on protein level in
cc-RCC. Moreover, we found that loss of CRHBP mRNA
expression is correlated with advanced, metastasized and
higher stages of disease. To our knowledge, tumor specific
reduction of CRHBP expression has not been reported in
any human malignancy so far, although results indicative of
a decreased expression of corticotropin-releasing hormone-
binding protein mRNA in pituitary adenomas have been
described before [21]. On the other hand, various studies
show that Ucn, CRFR1 and CRFR2 are differently regulated
and expressed in human cancer [10,11]. Moreover, several
in vitro and in vivo studies reported that activation of
CRFR2 suppresses the neovascularization through reduc-
tion of VEGF production. The loss of function, blocking or
gene knock out of CRFR2 has been found to cause an up-
regulation of VEGF in turn inducing neovascularization
[5,7,8]. This is in good concordance with our previous find-
ing that the CRFR2 protein is not expressed in vessels of
cc-RCC [11], a cancer that is characterized by increased
VEGF levels and substantial neovascularization. CRHBP is
the only example of a neuro-peptide-binding protein that
circulates in the plasma. CRHBP binds the Corticotropin –
Releasing factor (CRF) and other CRF-family peptides, e.g.
Urocortin (Ucn) with a high affinity but does not interact
with Ucn3 [22,23]. It has been hypothesized that extracellu-
lar CRHBP may serve as a ligand trap thus potentially beinvolved in regulation of the bound/free ligand equilibrium
of locally required peptides and representing a potential
pharmacological therapeutic target [24,25]. Considering
that ligand concentrations of locally required peptides have
been shown to affect proliferation and angiogenesis of can-
cer cells, we suppose that the reduction of CRHBP mRNA
and protein expression in tumors also contribute in those
pivotal tumorigenic processes.
Immunopositivity was detected mainly in proximal tubu-
lar epithelial cells of normal tissue for both CRHBP itself in
the present study as well as for the CRHBP ligand Ucn in a
previous analysis [11], hence also supporting the hypothesis
that CRHBP is involved in tumor specific alterations of the
UCN system. Finally this point of view, is strengthened by
our statistical findings revealing a significant relationship
between reduced tumoral mRNA expression levels and the
state of more aggressive tumors in cc-RCC. Considering
that previous analyses support the relevance of the UCN
system for human carcinogenesis including also renal can-
cer, we hypothesize that alteration of CRHBP as a putative
modulator of UCN levels may also contribute to the devel-
opment and course of cc-RCC.
Although we found reduction of both, mRNA levels and
immunopositivity on protein levels in cc-RCC tissue com-
pared to normal kidney, this study obviously does not allow
functional implications about the role of CRHBP in cc-
RCC. While a direct head to head association between
mRNA and protein levels has not been shown in our study,
it is known that epigenetic changes including altered ex-
pression of micro- or long non-coding RNA may effect
protein expression after transcription. Such a candidate
epigenetic effector is miR-200bc/429 which has already
been annotated to the CRHBP gene (UCSC human genome
browser) [26]. Therefore functional analyses such as
targeted knock out of CRHBP gene in a cc-RCC tumor
model or epigenetic characterization of the UCN system
should provide an improved understanding of the CRHBP
contribution to the pathogenesis of cc-RCC.
Interestingly, Ucn family peptides have also been
detected in human circulation and urine [4,27] while
CRHBP expression beside those observed in normal tu-
bules of the kidney is also found in podocytes of renal
glomeruli. Whether Ucn and CRHBP levels in blood and
urine become altered and possibly affect renal cancer
progression or can serve as biomarker therefore appear
as further relevant questions remaining to be clarified in
future studies.Conclusion
In conclusion our data give evidence that altered CRHBP
expression as part of the UCN system is involved in kid-
ney cancer. Our results underline the potential biological
relevance of the CRF peptide family for renal cancer and
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molecular therapeutic approaches.
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